Advertisement

Treatment of Hepatitis C After Liver Transplantation

  • James R. BurtonJr.
  • Norah A. Terrault
  • Jennifer J. Kiser
  • Gregory T. Everson
Chapter

Abstract

The goal of hepatitis C virus (HCV) treatment in liver transplant (LT) recipients is to prevent graft loss and liver-related complications. Currently, the primary approach to the management of transplant recipients with HCV has been to treat after transplantation (Table 4.1). Antiviral therapy can be undertaken early, within the first 6 months post-LT, when recurrent viremia is documented, but prior to the presence of histologic criteria for treatment. This is often termed preemptive therapy. More commonly, treatment with antiviral therapy is reserved for those with recurrent and progressive histologic disease. Experts recommend treatment for patients with moderate to severe necroinflammatory activity or mild to moderate fibrosis (F2 or greater). Peginterferon and ribavirin has been the mainstay of posttransplant therapy for the past 15 years. With the recent approval of the first direct-acting antiviral (DAA) drugs—NS3/4A protease inhibitors—the standard of care for patients with genotype 1 HCV infection has changed to a triple drug regimen of peg-IFN, RBV, and either telaprevir or boceprevir. Since the majority of transplant recipients with HCV are infected with HCV genotype 1, this offers a significant opportunity to improve outcomes in these patients. Although, triple therapy is not approved for use in transplant recipients, off-label use is occurring due to significant need for more efficacious therapies in patients with progressive or severe recurrent disease. However, significant challenges including a higher risk of adverse events and more drug–drug interactions have been identified in early reports. In the future, DAA drugs with improved tolerability and less drug–drug interactions may allow greater ease of use, better tolerability, and higher rates of viral clearance.

Keywords

Hepatitis C Liver transplantation Antiviral therapy Peginterferon Ribavirin Telaprevir Boceprevir Simeprevir Sofosbuvir Daclatasvir Faldaprevir 

References

  1. 1.
    Terrault NA. Prophylactic and preemptive therapies for hepatitis C virus-infected patients undergoing liver transplantation. Liver Transpl. 2003;9:S95–100.PubMedCrossRefGoogle Scholar
  2. 2.
    Wiesner R, Sorrell M, Villamil F, International Liver Transplantation Society Expert P. Report of the first international liver transplantation society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl. 2003;9:S1–9.Google Scholar
  3. 3.
    Sugawara Y, Makuuchi M, Matsui Y, et al. Preemptive therapy for hepatitis C virus after living-donor liver transplantation. Transplantation. 2004;78:1308–11.PubMedCrossRefGoogle Scholar
  4. 4.
    Shergill AK, Khalili M, Straley S, et al. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant. 2005;5:118–24.PubMedCrossRefGoogle Scholar
  5. 5.
    Bzowej N, Nelson DR, Terrault NA, et al. PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl. 2011;17:528–38.PubMedCrossRefGoogle Scholar
  6. 6.
    Chalasani N, Manzarbeitia C, Ferenci P, et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology. 2005;41:289–98.PubMedCrossRefGoogle Scholar
  7. 7.
    Xirouchakis E, Triantos C, Manousou P, et al. Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies. J Viral Hepat. 2008;15:699–709.PubMedCrossRefGoogle Scholar
  8. 8.
    Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol. 2008;49(2):274–87.PubMedCrossRefGoogle Scholar
  9. 9.
    Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant. 2006;6:1586–99.PubMedCrossRefGoogle Scholar
  10. 10.
    Lange CM, Moradpour D, Doehring A, et al. Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. J Hepatol. 2011;55:322–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Duarte-Rojo A, Veldt BJ, Goldstein DD, et al. The course of posttransplant hepatitis C infection: comparative impact of donor and recipient source of the favorable IL28B genotype and other variables. Transplantation. 2012;94:197–203.PubMedCrossRefGoogle Scholar
  12. 12.
    Fukuhara T, Taketomi A, Motomura T, et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology. 2010;139:1577–85, 85 e1–3.PubMedCrossRefGoogle Scholar
  13. 13.
    Coto-Llerena M, Perez-Del-Pulgar S, Crespo G, et al. Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation. Am J Transplant. 2011;11:1051–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Kawaoka T, Takahashi S, Takaki S, et al. IL28B SNP of donors and recipients can predict virological response to PEGIFN/RBV therapy in patients with recurrent hepatitis C after living donor liver transplantation. J Gastroenterol Hepat. 2012 Sep;27:1467–72.CrossRefGoogle Scholar
  15. 15.
    Oton E, Barcena R, Moreno-Planas JM, et al. Hepatitis C recurrence after liver transplantation: viral and histologic response to full-dose Peg-interferon and ribavirin. Am J Transplant. 2006;6:2348.PubMedCrossRefGoogle Scholar
  16. 16.
    Gordon FD, Kwo P, Ghalib R, et al. Peginterferon-alpha-2b and Ribavirin for hepatitis C recurrence postorthotopic liver transplantation. J Clin Gastroenterol. 2012;46:700–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Roche B, Sebagh M, Canfora ML, et al. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl. 2008;14:1766–77.PubMedCrossRefGoogle Scholar
  18. 18.
    Selzner N, Renner E, Selzner M, et al. Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. Transplantation. 2009;88:1214–21.PubMedCrossRefGoogle Scholar
  19. 19.
    Berenguer M, Palau A, Aguilera V, Rayon JM, Juan FS, Prieto M. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant. 2008;8:679–87.PubMedCrossRefGoogle Scholar
  20. 20.
    Veldt BJ, Poterucha JJ, Watt KD, et al. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transplant. 2008;8:2426–33.PubMedCrossRefGoogle Scholar
  21. 21.
    Berenguer M, Prieto M, Palau A, et al. Recurrent hepatitis C genotype 1b following liver transplantation: treatment with combination interferon-ribavirin therapy. Eur J Gastroenterol Hepatol. 2004;16:1207–12.PubMedCrossRefGoogle Scholar
  22. 22.
    Bizollon T, Pradat P, Mabrut JY, et al. Histological benefit of retreatment by pegylated interferon alfa-2b and ribavirin in patients with recurrent hepatitis C virus infection posttransplantation. Am J Transplant. 2007;7:448–53.PubMedCrossRefGoogle Scholar
  23. 23.
    Gurusamy K, Tsochatzis E, Xirouchakis E, Burroughs A, Davidson B. Antiviral therapy for recurrent liver graft infection with hepatitis C virus. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD006803.Google Scholar
  24. 24.
    Berenguer M, Aguilera V, Rubin A, Ortiz C, Jimenez M, Prieto M. Comparison of two non-contemporaneous HCV-liver transplant cohorts: strategies to improve the efficacy of antiviral therapy. J Hepatol. 2012;56:1310–6.PubMedCrossRefGoogle Scholar
  25. 25.
    Levitsky J, Fiel MI, Norvell JP, et al. Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. Gastroenterology. 2012;142:1132–9.e1.PubMedCrossRefGoogle Scholar
  26. 26.
    Kugelmas M, Osgood MJ, Trotter JF, et al. Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection. Liver Transpl. 2003;9:1159–65.PubMedCrossRefGoogle Scholar
  27. 27.
    Bertuzzo VR, Cescon M, Morelli MC, et al. Long-term antiviral treatment for recurrent hepatitis C after liver transplantation. Dig Liver Dis. 2012;44:861–67.PubMedCrossRefGoogle Scholar
  28. 28.
    Calmus Y, Duvoux C, Pageaux G, et al. Treatment of recurrent HCV infection following liver transplantation: results of a multicenter, randomized, versus placebo, trial of ribavirin alone as maintenance therapy after one year of PegIFNalpha-2a plus ribavirin. J Hepatol. 2012;57:564–71.PubMedCrossRefGoogle Scholar
  29. 29.
    Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405–16.PubMedCrossRefGoogle Scholar
  30. 30.
    Zeuzem S, Andreone P, Pol S, Laawitz E, Diego M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364:2417–28.PubMedCrossRefGoogle Scholar
  31. 31.
    Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;264:1207–17.CrossRefGoogle Scholar
  32. 32.
    Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011 Mar 31;364:1195–206.PubMedCrossRefGoogle Scholar
  33. 33.
    Hezode C, Dorival C, Zoulim F, Larrey DG, Pol S, Cacoub P, et al. Safety and efficacy of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin in 455 cirrhotic nonresponders. Week 16 analysis of the French early access program (ANRS CO20-CUPIC) in real-life setting. Hepatology. 2012;56(Suppl):51.Google Scholar
  34. 34.
    Verna EC, Terry N, Lukose T, Mentore K, Olsen SK, et al. High early response rates with protease inhibitor triple therapy in a multicenter cohort of HCV-infected patients awaiting liver transplantation. Hepatology. 2012;56(Suppl):A52.Google Scholar
  35. 35.
    Garg V, Heeswijk R van, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology. 2011;54:20–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Hulskotte E, Gupta S, Xuan F, Zutven M van, O’Mara E, Feng HP, et al. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology. 2012;56:1622–30.PubMedCrossRefGoogle Scholar
  37. 37.
    Burton JR Jr, Everson GT. Initial experience with telaprevir for treating hepatitis C virus in liver recipients: virologic response, safety and tolerability. Am J Transpl. 2012;12 Suppl 3:LB01.Google Scholar
  38. 38.
    Werner CR, Egetemeyr DP, Lauer UM, Nadalin S, Konigsrainer A, Malek NP, et al. Short report: telaprevir-based triple therapy in liver transplanted HCV patients: a 112 week pilot study providing safety and efficacy. Liver Transpl. 2012;18:1464–70.PubMedCrossRefGoogle Scholar
  39. 39.
    Coilly A, Roche T, Antonini T, Samuel D, Duclos-Vallee J. Efficacy and safety of protease inhibitors for hepatitis C recurrence after liver transplantation; a first multicentric experience. Hepatology. 2012;56(Suppl):9.Google Scholar
  40. 40.
    Pungpapong S, Murphy JL, Henry TM, Ryland K, Satyanarayana R, Rosser B, et al. Preliminary experience using telaprevir with peginterferon and ribavirin for treatment of HCV genotype 1 after liver transplantation. Hepatology. 2012;56(Suppl):10.Google Scholar
  41. 41.
    Aqel B, Carey EJ, Byrne TJ, Rakela J, Vargas HE. Multicenter preliminary experience utilizing boceprevir with pegylated interferon and ribavirin for treatment of recurrent hepatitis C genotype 1 after liver transplantation. Hepatology. 2012;56(Suppl):706.Google Scholar
  42. 42.
    O’Leary JG, McKenna GJ, Klintmalm G, Davis GL. 100 % cEVR post-liver transplant with telaprevir triple drug therapy. Hepatology. 2012;56(Suppl):707.Google Scholar
  43. 43.
    Mantry PS, Wu C, Weinstein JS, Mubarak A, Nazario HE, Madani B, et al. Early and end of treatment virologic responses in patients with hepatitis C genotype 1 recurrence after liver transplant treated with triple therapy using telaprevir: a single center experience. Hepatology. 2012;56(Suppl):712.Google Scholar
  44. 44.
    Nair S, Waters B. Telaprevir can be used effectively and saffetly to treat recurrent HCV in liver transplant recipients receiving tacrolimus based immunosuppression. Hepatology. 2012;56(Suppl):720.Google Scholar
  45. 45.
    Burton JR Jr, O’Leary JG, Verna EC, Lai JC, Everson GT, Trotter JF, et al. A multicenter study of protease inhibitor-triple therapy in HCV-infected liver transplant recipients: report from the CRUSH-C group. Hepatology. 2012;56(Suppl):211.Google Scholar
  46. 46.
    Sulkowski MS, Poordad F, Manns MP, Bronowicki JP, Reddy KR, Harrison SA, et al. Anemia during treatment with peginterferon alfa-2b/ribavirin and boceprevir: analysis from the SPRINT-2 trial. Hepatology. 2013;57(3):974–84.PubMedCrossRefGoogle Scholar
  47. 47.
    Sulkowski MS, Robers S, Afdhal N, Andreone P, Diago M, Pols S, et al. Ribavirin dose modification in treatment naive and previously treated patients who received telaprevir combination treatment: no impact on sustained virologic response in phase 3 studies [abstract]. J Hepatol. 2012;56 Suppl 2:S459–60.CrossRefGoogle Scholar
  48. 48.
    Fontana RJ, Hughes EA, Appelman H, Hindes R, Dimitrova D, Bifano M. A case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C following liver retransplantation. Liver Transpl. 2012;18:1053–9.PubMedCrossRefGoogle Scholar
  49. 49.
    Sulkowski MS, Ceasu E, Asselah T, et al. SILEN-C1: sustained virologic response (SVR) and safety of BI201335 combined with peginterferon alfa-2a and ribavirin (p/R) in treatment-naive patients with chronic genotype 1 HCV infection. Paper presented at 46th Annual Meeting of the European Association for the Study of the Liver, March 30–April 3, 2011; Berlin, Germany.Google Scholar
  50. 50.
    Fried MW, Buti M, Dore GJ, et al. TMC435 in combination with peginterferon and ribavirin in treatment naive HCV genotype 1 patients: final analysis of the pillar phase IIb study. Paper presented at 62nd Annual Meeting of the American Assocation for the Study of Liver Diseases, November 4–8, 2011; San Francisco, CA.Google Scholar
  51. 51.
    Hezode C, Hirschfield G, Ghesquiere W, et al. BMS-790052, a NS5A replication complex inhibitor, combined with peginterferon alfa-2a and ribavirin in treatment-naive HCV genotype 1 or 4 patients: phase 2b AI444010 study interim week 12 results. Paper presented at 62nd Annual Meeting of the American Association for the Study of Liver Diseases, November 4–8, 2011; San Francisco, CA.Google Scholar
  52. 52.
    Hassanein T, Lawitz E, Crespo I, et al. Once daily sofosbuvir (GS-7977) plus PEG/RBV: high early response rates are maintained during post-treatment follow-up in treatment-naive patients with HCV genotype 1, 4, and 6 infection in the ATOMIC study [abstract 230]. Paper presented at 63rd Annual Meeting of the American Association for the Study of Liver Diseases, November 9–13, 2012; Boston, MA.Google Scholar
  53. 53.
    Kowdley KV, Lawitz E, Poordad F, et al. A 12-week interferon-free treatment regimen with ABT-450/r, ABT-267, ABT-333 and ribavirin achieves svr12 rates (observed data) of 99 % in treatment-naive patients and 93 % in prior null responders with HCV genotype 1 infection [abstract LB1]. Paper presented at 63rd Annual Meeting of the American Association for the Study of Liver Diseases, November 9–13, 2012; Boston, MA.Google Scholar
  54. 54.
    Sulkowski MS, Gardiner D, Rodriguez-Torres M, et al. All-oral combination of DCV + SOF ± RBV in treatment-naive patients with HCV GT 1, 2 or 3 [abstract LB2]. Paper presented at 63rd Annual Meeting of the American Association for the Study of Liver Diseases, November 9–13, 2012; Boston, MA.Google Scholar
  55. 55.
    Everson GT, Sims KD, Rodriguez-Torres M, et al. An interferon-free, ribavirin-free 12-week regimen of daclatasvir (DCV), Asunaprevir (ASV), and BMS-791325 Yielded SVR4 of 94 % in treatment-naive patients with genotype (GT) 1 chronic hepatitis C virus (HCV) infection [abstract LB3]. Paper presented at 63rd Annual Meeting of the American Association for the Study of Liver Diseases, November 9–13, 2012; Boston, MA.Google Scholar
  56. 56.
    Lok AS, Gardiner D, Hezode C, et al. Sustained virologic response in chronic HCV genotype (GT) 1-infected null responders with combination of daclatasvir (DCV; NS5A Inhibitor) and asunaprevir (ASV; NS3 Inhibitor) with or without peginterferon alfa-2a/ribavirin (PEG/RBV) [abstract 79]. Paper presented at 63rd Annual Meeting of the American Association for the Study of Liver Diseases, November 9–13, 2012; Boston, MA.Google Scholar
  57. 57.
    Feld JJ, Jacobson IM, Jensen DM, et al. Up to 100 % SVR4 rates with ritonavir-boosted danoprevir (DNVr), mericitabine (MCB), and ribavirin ® +/- peginterferon alfa-2a (40KD) (P) in HCV genotype 1-infected partial and null responders: results from the MATTERHORN study [abstract 81]. Paper presented at 63rd Annual Meeting of the American Assocation for the Study of Liver Diseases, November 9–13, 2012; Boston, MA.Google Scholar
  58. 58.
    Thompson AJ, Shiffman ML, Rossaro L, et al. Six weeks of a NS5A inhibitor (GS-5885), protease inhibitor (GS-9451) plus peginterferon/ribavirin (PR) achieves high SVR rates in genotype 1 IL28B CC treatment naive HCV patients: interim results of a prospective, randomized trial [abstract 759]. Paper presented at 63rd Annual Meeting of the American Association for the Study of Liver Diseases, November 9–13, 2012; Boston, MA.Google Scholar
  59. 59.
    Kiser J, Burton JR, Everson GT. Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol. 2013 Jul 2. 401: 10.1038/nrgastro.2013.106Google Scholar
  60. 60.
    Burton JR, Everson GT. Management of the transplant recipient with chronic hepatitis C. Clin Liver Dis. 2013;17:73–91.PubMedCrossRefGoogle Scholar
  61. 61.
    Muir AJ, Shiffman ML, Zaman A, et al. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology. 2010;52:822–32.PubMedCrossRefGoogle Scholar
  62. 62.
    Sekar V, Verloes R, Meyvisch P, Spittaels K, Akuma SH, De Smedt G. TMC435 and drug interactions: evaluation of metabolic interactions for TMC435 via cytochrome P450 (CYP) enzymes in healthy volunteers. Paper presented at 45th European Assocation for the Study of the Liver, April 14–18, 2010; Vienna, Austria.Google Scholar
  63. 63.
    Huisman MT, Snoeys J, Monbaliu J, Martens M, Sekar V, Raoof A. In vitro studies investigating the mechanism of interaction between TMC435 and hepatic transporters. Paper presented at 61st Annual Meeting of the American Association for the Study of Liver Diseases, October 30-November 3, 2010; Boston, MA.Google Scholar
  64. 64.
    Ouwerkerk-Mahadevan S, Simion A, Mortier S, Peeters M, Beumont-Mauviel M. No clinically significant interaction between the investigational HCV protease inhibitor TMC435 and the immunosuppressives cyclosporine and tacrolimus [abstract 80]. Paper presented at 63rd Annual Meeting of the American Association for the Study of Liver Diseases, November 9–13, 2012; Boston, MA.Google Scholar
  65. 65.
    Sabo JP, Kashuba ADM, Ballow CH, et al. Cytochrome P450 (CYP) interactions with the HCV protease inhibitor faldaprevir (BI 201335) in healthy volunteers [abstract A-1248]. Paper presented at The 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 9–12, 2012; San Francisco, CA.Google Scholar
  66. 66.
    Sane R, Podila L, Mathur A, et al. Mechanism of isolated unconjugated hyperbilirubinemia induced by the HCV NS3/4A protease inhibitor BI 201335. Paper presented at 46th Annual Meeting of the European Association for the Study of the Liver, March 30–April 20, 2011; Berlin, Germany.Google Scholar
  67. 67.
    Gish RG, Meanwell NA. The NS5A replication complex inhibitors: difference makers? Clin Liver Dis. Aug. 2011;15(3):627–39.Google Scholar
  68. 68.
    Bifano M, Sevinsky H, Persson A, et al. Daclatasvir has no clinically significant effect on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate in healthy female subjects. Paper presented at American Association for the Study of Liver Diseases, November 5–8, 2011; San Francisco, CA.Google Scholar
  69. 69.
    Cornpropst M, Denning J, Clemons D, et al. The effect of renal impairment and end stage renal disease on the single-dose pharmacokinetics of GS-7977. Paper presented at 47th Annual Meeting of the European Association for the Study of the Liver April 18–22, 2012; Barcelona, Spain.Google Scholar
  70. 70.
    Mathias A, Cornpropst M, Clemons D, Denning J, Symonds W. No clinically significant pharmacokinetic drug-drug interactions between sofosbuvir (GS-7977) and the immunosuppressants, cyclosporine a or tacrolimus in healthy volunteers [abstract 1869]. Paper presented at 63rd Annual Meeting of the American Association for the Study of Liver Diseases, November 9–13, 2012; Boston, MA.Google Scholar
  71. 71.
    Lok AS, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med. 2012;366:216–24.PubMedCrossRefGoogle Scholar
  72. 72.
    Chayama K, et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology. 2012;55:742–8.PubMedCrossRefGoogle Scholar
  73. 73.
    Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds W, Hindes RG. Berrey MM. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013;368:34–44.PubMedCrossRefGoogle Scholar
  74. 74.
    Poordad F, Lawitz E, Kowdley KV, Cohen DE, Podsecki T, Sigglekow S, Heckaman M, Larsen L, Menon R, Koev G, Tripathi R, Pilot-Matias T, Bernstein B. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med. 2013;368:45–53.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • James R. BurtonJr.
    • 1
  • Norah A. Terrault
    • 2
  • Jennifer J. Kiser
    • 3
  • Gregory T. Everson
    • 1
  1. 1.Gastroenterology and Hepatology Division, Department of MedicineUniversity of Colorado DenverAuroraUSA
  2. 2.Gastroenterology DepartmentUniversity of California San FranciscoSan FranciscoUSA
  3. 3.Department of Pharmaceutical Sciences, School of PharmacyUniversity of Colorado DenverAuroraUSA

Personalised recommendations